March 09, 2009 -- Article One Partners LLC has discovered new prior art impacting the validity of Merck & Co.'s SINGULAIR U.S. drug patent. A request is being filed today with the U.S. Patent Office to review the patent in a reexamination proceeding. An independent law firm and an independent expert join Article One's opinion that a substantial new question of patent validity is raised by the success of Article One's research and should be reviewed by the Patent Office.
The details can be read here.
No comments:
Post a Comment